Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies
Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients
Ligand Reports Third Quarter 2020 Financial Results
Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment
Ligand Provides Highlights from Today’s Investor Day Event
Ligand’s Third Quarter Financial Results to be Reported October 30th
Ligand to Divest Vernalis Research Operations
Ligand to Host Virtual Investor Day on October 20th
Ligand Completes Acquisition of Pfenex Inc.
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
